First-line treatment of hypertension: critical appraisal of potential role of aliskiren and hydrochlorothiazide in a fixed combination

References

• KearneyPMWheltonMReynoldsKMuntnerPWheltonPKHeJGlobal burden of hypertension: Analysis of worldwide dataLancet2005365945521722315652604
   PubMed Web of Science ®Google Scholar
• WhitworthJA2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertensionJ Hypertens200321111983199214597836
   PubMed Web of Science ®Google Scholar
• ManciaGLaurentSAgabiti-RoseiEReappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force documentBlood Press200918630834720001654
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRSeventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension20034261206125214656957
   PubMed Web of Science ®Google Scholar
• WangYRAlexanderGCStaffordRSOutpatient hypertension treatment, treatment intensification, and control in Western Europe and the United StatesArch Intern Med2007167214114717242314
   PubMedGoogle Scholar
• Wolf-MaierKCooperRSKramerHHypertension treatment and control in five European countries, Canada, and the United StatesHypertension2004431101714638619
   PubMed Web of Science ®Google Scholar
• WaldDSLawMMorrisJKBestwickJPWaldNJCombination therapy versus monotherapy in reducing blood pressure: Meta-analysis on 11,000 participants from 42 trialsAm J Med2009122329030019272490
   PubMed Web of Science ®Google Scholar
• MatersonBJRedaDJCushmanWCSingle-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive AgentsN Engl J Med1993328139149218446138
   PubMed Web of Science ®Google Scholar
• GradmanAHBasileJNCarterBLCombination therapy in hypertensionJ Am Soc Hypertens201042909820400053
   PubMed Web of Science ®Google Scholar
• GuptaAKArshadSPoulterNRCompliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: A meta-analysisHypertension201055239940720026768
   PubMed Web of Science ®Google Scholar
• DzauVThe cardiovascular continuum and renin-angiotensin-aldosterone system blockadeJ Hypertens Suppl2005231S9S1715821452
   PubMedGoogle Scholar
• ConlinPRGerthWCFoxJRoehmJBBoccuzziSJFour-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classesClin Ther200123121999201011813934
   PubMed Web of Science ®Google Scholar
• WaeberBCombination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertensionExpert Rev Cardiovasc Ther200311435015030296
   PubMedGoogle Scholar
• FerrarioCMStrawnWBRole of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular diseaseAm J Cardiol200698112112816784934
   PubMed Web of Science ®Google Scholar
• WollertKCDrexlerHThe renin-angiotensin system and experimental heart failureCardiovasc Res199943483884910615411
   PubMed Web of Science ®Google Scholar
• DerkxFHSchalekampMAHuman prorenin: Pathophysiology and clinical implicationsClin Exp Hypertens A1988106121312253066528
   PubMedGoogle Scholar
• DanserAHDeinumJRenin, prorenin and the putative (pro)renin receptorHypertension20054651069107616186442
   PubMed Web of Science ®Google Scholar
• TschopeCSchultheissHPWaltherTMultiple interactions between the renin-angiotensin and the kallikrein-kinin systems: Role of ACE inhibition and AT1 receptor blockadeJ Cardiovasc Pharmacol200239447848711904521
   PubMed Web of Science ®Google Scholar
• HoogwerfBJRenin-angiotensin system blockade and cardiovascular and renal protectionAm J Cardiol2010105Suppl 130A35A
   Google Scholar
• van den MeirackerAHMan in ‘t VeldAJAdmiraalPJPartial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: Does it exist and does it affect the antihypertensive response?J Hypertens19921088038121325513
   PubMed Web of Science ®Google Scholar
• SureshkumarKKRenin inhibition with aliskiren in hypertension: Focus on aliskiren/hydrochlorothiazide combination therapyVasc Health Risk Manag2008461205122019337534
   PubMedGoogle Scholar
• KimSIwaoHMolecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseasesPharmacol Rev2000521113410699153
   PubMed Web of Science ®Google Scholar
• VaidyanathanSJarugulaVDieterichHAHowardDDoleWPClinical pharmacokinetics and pharmacodynamics of aliskirenClin Pharmacokinet200847851553118611061
   PubMed Web of Science ®Google Scholar
• AziziMWebbRNussbergerJHollenbergNKRenin inhibition with aliskiren: Where are we now, and where are we going?J Hypertens200624224325616508564
   PubMed Web of Science ®Google Scholar
• WaldmeierFGlaenzelUWirzBAbsorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteersDrug Metab Dispos20073581418142817510248
   PubMed Web of Science ®Google Scholar
• NussbergerJWuerznerGJensenCBrunnerHRAngiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): Comparison with enalaprilHypertension2002391E1E811799102
   PubMed Web of Science ®Google Scholar
• AziziMMenardJBisseryAPharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruptionJ Am Soc Nephrol200415123126313315579516
   PubMed Web of Science ®Google Scholar
• DanserAH(Pro)renin receptors: Are they biologically relevant?Curr Opin Nephrol Hypertens2009181747819077693
   PubMed Web of Science ®Google Scholar
• AndersenKWeinbergerMHConstanceCMComparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertensionJ Renin Angiotensin Aldosterone Syst200910315716719617271
   PubMed Web of Science ®Google Scholar
• ErnstMEMoserMUse of diuretics in patients with hypertensionN Engl J Med2009361222153216419940300
   PubMed Web of Science ®Google Scholar
• VillamilAChrysantSGCalhounDRenin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazideJ Hypertens200725121722617143194
   PubMed Web of Science ®Google Scholar
• JordanJEngeliSBoyeSWle BretonSKeefeDLDirect renin inhibition with aliskiren in obese patients with arterial hypertensionHypertension20074951047105517353513
   PubMed Web of Science ®Google Scholar
• WestermannDSchmiederRSchultheissHPTschopeCRenin inhibitors, clinical experienceJ Mol Med200886669169518437334
   PubMed Web of Science ®Google Scholar
• PintoRGradmanAHDirect renin inhibition: An updateCurr Hypertens Rep200911645646219895758
   PubMed Web of Science ®Google Scholar
• MusiniVMFortinPMBassettKWrightJMBlood pressure lowering efficacy of renin inhibitors for primary hypertensionCochrane Database Syst Rev20084CD00706618843743
   PubMed Web of Science ®Google Scholar
• StantonAVGradmanAHSchmiederRENussbergerJSarangapaniRPrescottMFAliskiren monotherapy does not cause paradoxical blood pressure rises: Meta-analysis of data from 8 clinical trialsHypertension2010551546019917876
   PubMed Web of Science ®Google Scholar
• KushiroTItakuraHAboYGotouHTeraoSKeefeDLAliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertensionHypertens Res20062912997100517378372
   PubMed Web of Science ®Google Scholar
• GradmanAHSchmiederRELinsRLNussbergerJChiangYBedigianMPAliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patientsCirculation200511181012101815723979
   PubMed Web of Science ®Google Scholar
• StantonAJensenCNussbergerJO’BrienEBlood pressure lowering in essential hypertension with an oral renin inhibitor, aliskirenHypertension20034261137114314597641
   PubMed Web of Science ®Google Scholar
• PoolJLSchmiederREAziziMAliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartanAm J Hypertens2007201112017198906
   PubMed Web of Science ®Google Scholar
• ErnstMECarterBLGoerdtCJComparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressureHypertension200647335235816432050
   PubMed Web of Science ®Google Scholar
• OnuigboMAALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analysesArch Intern Med2009169191810
   Google Scholar
• MesserliFHBangaloreSJuliusSRisk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertensionCirculation2008117202706271518490538
   PubMed Web of Science ®Google Scholar
• CalhounDAVillamilASChrysantSGSchoberBFangHZhangJAntihypertensive efficacy of aliskiren/hydrochlorothiazide (HCT) combinations in patients with stage 2 hypertension: Subgroup analysis of a randomized, double-blind, factorial trialHypertension2008524E97
   Web of Science ®Google Scholar
• DuprezDAMungerMABothaJKeefeDLCharneyANAliskiren for geriatric lowering of systolic hypertension: A randomized controlled trialJ Hum Hypertens201024960060820033075
   PubMed Web of Science ®Google Scholar
• NickenigGSimanenkovVLemboGEfficacy of aliskiren/hydrochlorothiazide single-pill combinations in aliskiren non-respondersBlood Press Suppl20082314019203020
   PubMedGoogle Scholar
• BlumensteinMRomaszkoJCalderonAAntihypertensive efficacy and tolerability of aliskiren/hydrochlorothiazide (HCT) single-pill combinations in patients who are non-responsive to HCT 25 mg aloneCurr Med Res Opin200925490391019245300
   PubMed Web of Science ®Google Scholar
• WeirMRBushCAndersonDRZhangJKeefeDSatlinAAnti-hypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: A pooled analysisJ Am Soc Hypertens20071426427720409858
   PubMed Web of Science ®Google Scholar
• MullerDNDererWDechendRAliskiren – mode of action and preclinical dataJ Mol Med200886665966218443751
   PubMed Web of Science ®Google Scholar
• WestermannDRiadALettauORenin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressureHypertension20085261068107518955663
   PubMed Web of Science ®Google Scholar
• McMurrayJJPittBLatiniREffects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failureCirc Heart Fail200811172419808266
   PubMed Web of Science ®Google Scholar
• SolomonSDAppelbaumEManningWJEffect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophyCirculation2009119453053719153265
   PubMed Web of Science ®Google Scholar
• JacobshagenCWestermannDHolubarschCBohmMHotline update of clinical trials and registries presented at the American College of Cardiology Congress 2010: ACCORD, INVEST, NAVIGATOR, RACE II, SORT OUT III, CSP-474, DOSE, ASPIRE and moreClin Res Cardiol201099633734420396895
   PubMedGoogle Scholar
• ParvingHHPerssonFLewisJBLewisEJHollenbergNKAliskiren combined with losartan in type 2 diabetes and nephropathyN Engl J Med2008358232433244618525041
   PubMed Web of Science ®Google Scholar
• StrasserRHPuigJGFarsangCCroketMLiJvan IngenHA comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertensionJ Hum Hypertens2007211078078717541390
   PubMed Web of Science ®Google Scholar